Northrop Grumman has staged a sharp reversal since last week's note: the stock jumped 7.8% to close at $549.04, recouping most of what it lost through June and closing the gap to peers who have also had a strong week in defense.
The rally puts a different frame on an otherwise unchanged analyst picture. Targets have been drifting lower all quarter — Citigroup cut to $587 on July 1, Jefferies trimmed to $580 on June 26, and both Morgan Stanley and UBS marked down their numbers in April after Q1 results. Every firm kept a positive rating, so the direction of travel is cautious rather than negative. The mean consensus target is near $687, which implies about 25% upside from current levels — meaningful, but the gap has been narrowing as targets come down faster than the stock has recovered. The Street is lowering the bar ahead of the July 21 print, not raising it.
The lending market offers no counternarrative here — it is simply uninformative. Availability is essentially uncapped, with over 117 million shares free to borrow against a short position of just 2.2 million. SI runs at 1.6% of the free float, up modestly on the week but too small to matter. Cost to borrow dropped sharply to 0.26%, its lowest level of the past month. Nothing in the borrow market suggests any structural short thesis building ahead of earnings — shorts at this level are noise, not a signal. Options positioning is similarly neutral: the put/call ratio is 0.95, almost exactly in line with its 20-day average, and the z-score is barely above zero. There is no defensive hedging visible in the options tape despite the July 21 earnings date two weeks out.
NOC's 7.8% weekly gain pulls it into line with close peers. RTX rose 7.2% on the week, GD gained 7.6%, and LMT added 6.6%. The move looks sector-wide rather than stock-specific — broad defense re-rating on macro sentiment rather than anything idiosyncratic to Northrop. DRS led the group with an 11% weekly gain, while LHX lagged at just over 2%. NOC is no longer the week's underperformer, but it has not broken away from the pack either.
Institutional positioning tells the story of a stock owned by the usual long-duration holders. Capital Research lifted its stake to nearly 11% of shares, BlackRock added roughly half a million shares to its 7.7% position, and Wellington built a meaningful new stake of 3.5% in recent months. These are patient, fundamental-driven owners. There is no sign of forced selling or aggressive rotation. The factor picture is mixed but not alarming: dividend score ranks in the 99th percentile, but EPS momentum over both 30- and 90-day windows is weak — 30th and 35th percentile respectively — and forward EPS growth ranks near the bottom of the universe at just the 2nd percentile. That last figure explains the target cuts more than anything else.
The Q1 print in April produced a one-day drop of 10.3% and a five-day loss of 12%. The prior quarter's result was softer but still negative. The pattern heading into July 21 is therefore less about whether the B-21 program is progressing and more about whether management can deliver guidance that stops the downward revision cycle — and whether the current $549 price adequately reflects the risk of another miss.
See the live data behind this article on ORTEX.
Open NOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
